Table 18Mayrand et al8: Sensitivity Analysis Varying Estimates of Screening Adherence*

StrategyColposcopiesIncremental ColposcopiesLife-YearsIncremental Life-YearsICLY
No intervention069016.30
Cytology, q3, age 21;
Cytology and HPV, q5, age 30
15315369153.21136.911
Cytology, q3, age 21;
Cytology and HPV, q3, age 30
2085569181.4628.252
Cytology, q2, age 21;
Cytology and HPV, q3, age 30
2928469201.9320.474
Cytology, q1, age 21;
Cytology and HPV, q3, age 30
41712569224.3022.376
*

Adherence to screening is assumed to be <100%. Results are presented as expected colposcopies per 1,000 women, incremental colposcopies, life-years, incremental life-years, and incremental colposcopies per life-year (ICLY) for strategies identified as efficient. Women are assumed to begin screening at age 21 years. For the combined cytology and HPV strategies, cytology-based screening is assumed before age 30 years, with a repeat cytology test for ASC-US results. The strategy of cytology and HPV testing is assumed to begin at age 30 years.

From: Addendum

Cover of Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force
Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force [Internet].
Evidence Syntheses, No. 86s.
Kulasingam SL, Havrilesky L, Ghebre R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.